TaylorE, AllenJD, HeylandA. Thyroid hormones reversibly inhibit metamorphic development in ophiuroid larvae. J Exp Biol, 2025; 228(3):JEB249351; doi: 10.1242/jeb.249351
2.
SepulvedaP, FerreiraAFF, SandovalC, et al.Thyroid hormone supplementation restores cognitive deficit, insulin signaling, and neuroinflammation in the hippocampus of a sporadic Alzheimer’s-like disease rat model. Cells, 2024; 13(21):1793; doi: 10.3390/cells13211793
3.
MaierJ, DoreR, OelkrugR, et al.Inhibition of thyroid hormone signaling in the zona incerta alters basal metabolic rate, behavior, and serum glucocorticoids in male mice. Thyroid, 2024; 34(10):1280–1291; doi: 10.1089/thy.2024.0209
4.
LiuY, NgL, LiuC, et al.Serotonergic and chemosensory brain areas and sensory ganglia expressing type 3 deiodinase mapped with Dio3Cre drivers. Endocrinology, 2025; 166(7):bqaf085; doi: 10.1210/endocr/bqaf085
5.
PanX, WangL, YangJ, et al.TRbeta activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA. Nat Commun, 2024; 15(1):8672; doi: 10.1038/s41467-024-52827-z
6.
HartmannHA, LobergMA, XuGJ, et al.Tenascin-C potentiates Wnt signaling in thyroid cancer. Endocrinology, 2025; 166(3):bqaf030; doi: 10.1210/endocr/bqaf030
7.
KrishnamoorthyGP, GloverAR, UntchBR, et al.RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs. J Exp Med, 2025; 222(5):e20241029; doi: 10.1084/jem.20241029
8.
NaironKG, NigamA, KhanalT, et al.RCAN1.4 regulates tumor cell engraftment and invasion in a thyroid cancer to lung metastasis-on-a-chip microphysiological system. Biofabrication, 2024; 17(1); doi: 10.1088/1758-5090/ad82e0
9.
PantinaVD, VeronaF, TurdoA, et al.Protocol for generation and engineering of thyroid cell lineages using CRISPR-Cas9 editing to recapitulate thyroid cancer histotype progression. STAR Protoc, 2024; 5(3):103263; doi: 10.1016/j.xpro.2024.103263
10.
UndeutschHJ, PosabellaA, KottonDN, et al.Protocol for directed differentiation of human induced pluripotent stem cells into thyroid follicular epithelial cells. STAR Protoc, 2025; 6(3):103979; doi: 10.1016/j.xpro.2025.103979
11.
RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association Management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841–985; doi: 10.1177/10507256251363120
12.
QiangJK, SutradharR, EverettK, et al.Association between serum thyrotropin and cancer recurrence in differentiated thyroid cancer: A population-based retrospective cohort study. Thyroid, 2025; 35(2):208–215; doi: 10.1089/thy.2024.0330
13.
XieP, ShenL, PengR, et al.Effects of low-dose methotrexate with Methimazole in patients with Graves’ disease: Results of a randomized clinical trial. J Clin Endocrinol Metab, 2025; 110(2):489–497; doi: 10.1210/clinem/dgae472
14.
KusA, SterenborgR, HaugEB, et al.Towards personalized TSH reference ranges: A genetic and population-based approach in three independent cohorts. Thyroid, 2024; 34(8):969–979; doi: 10.1089/thy.2024.0045
15.
AdamsR, MammenJS. Sex differences in risk for iatrogenic thyrotoxicosis among older adults: An analysis from real-world clinical data. Thyroid, 2025; 35(5):485–493; doi: 10.1089/thy.2024.0604
16.
BritoJP, HerrinJ, SwarnaKS, et al.GLP-1RA use and thyroid cancer risk. JAMA Otolaryngol Head Neck Surg, 2025; 151(3):243–252; doi: 10.1001/jamaoto.2024.4852
17.
BaxterSM, LundLC, AndersenJH, et al.Glucagon-Like Peptide 1 receptor agonists and risk of thyroid cancer: An international multisite cohort study. Thyroid, 2025; 35(1):69–78; doi: 10.1089/thy.2024.0387
18.
DucheminL, MoriceA, MoricePM, et al.Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials. Diabetes Obes Metab, 2025; 27(8):4607–4610; doi: 10.1111/dom.16504
19.
SilveriiGA, MarinelliC, BettariniC, et al.GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab, 2025; 27(8):4454–4468; doi: 10.1111/dom.16489
20.
MoralesDR, BuF, ViernesB, et al.Risk of thyroid tumors with GLP-1 receptor agonists: A retrospective cohort study. Diabetes Care, 2025; 48(8):1386–1394; doi: 10.2337/dc25-0154
21.
DongJ, StarkeyT, ChengVWT, et al.; UK weight and wellness research consortium. Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model—A UK weight and wellness cancer landscape analysis. Cancer Epidemiol, 2025; 97:102837; doi: 10.1016/j.canep.2025.102837
22.
Ramirez StiebenLA, BrunLR, Nasazzi DoddiP, et al.Antithyroid drugs and the dose-risk balance: A meta-analysis on agranulocytosis in hyperthyroidism. Endocrine, 2025; 90(2):391–403; doi: 10.1007/s12020-025-04372-y
23.
LiuW, DongZ, CaoW, et al.The natural course of low-risk papillary thyroid microcarcinoma during pregnancy: A prospective active surveillance study. Thyroid, 2025; 35(6):684–690; doi: 10.1089/thy.2024.0702
24.
SuK, LiuJ, RenX, et al.A fully autonomous robotic ultrasound system for thyroid scanning. Nat Commun, 2024; 15(1):4004; doi: 10.1038/s41467-024-48421-y
25.
ParkSI, BaekJH, LeeDH, et al.Radiofrequency ablation for the treatment of benign thyroid nodules: 10-year experience. Thyroid, 2024; 34(8):990–998; doi: 10.1089/thy.2024.0082
26.
YanL, LiYY, LiXY, et al.Thermal ablation for papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg, 2024; 151(1):9–17; doi: 10.1001/jamaoto.2024.3229
27.
ChoSJ, SuhCH, BaekJH, et al.Active surveillance for small papillary thyroid cancer: A systematic review and meta-analysis. Thyroid, 2019; 29(10):1399–1408; doi: 10.1089/thy.2019.0159
28.
Ledesma-LeonT, Solis-PazminoP, LincangoEP, et al.Ablation techniques or active surveillance compared to surgical resection in patients with low-risk papillary thyroid cancer: A systematic review and meta-analysis. Endocrine, 2024; 83(2):330–341; doi: 10.1007/s12020-023-03502-8
29.
van der MeerenMMD, BoersT, de GraafP, et al.Radiofrequency ablation for thyroid nodules (RATED Study)-analysis of a learning curve and predictors of success. J Clin Endocrinol Metab, 2025; 110(11):3201–3209; doi: 10.1210/clinem/dgaf058
30.
SugitaniI, NagaokaR, SaitouM, et al.Long-term outcomes of active surveillance for low-risk papillary thyroid carcinoma: Progression patterns and tumor calcification. World J Surg, 2025; 49(1):159–169; doi: 10.1002/wjs.12417
31.
SaitoY, MatsuzuK, AhmedAHA, et al.Lobectomy vs total thyroidectomy with ipsilateral lateral neck dissection for N1b Intermediate-Risk papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg, 2025; 151(2):105–112; doi: 10.1001/jamaoto.2024.3860
32.
LiX, GuiZ, XuC, et al.Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: A systematic review and meta-analysis. Int J Surg, 2025; 111(9):6343–6350; doi: 10.1097/JS9.0000000000002673
33.
JiXY, LiangWL, YuTT, et al.Thyroid lobectomy for unilateral TNM T1 and T2 papillary thyroid carcinoma patients with lateral lymph node metastasis. Surgery, 2025; 180(9):109028; doi: 10.1016/j.surg.2024.109028
34.
ShiX, ShenCK, LiuCQ, et al.Hemithyroidectomy versus total thyroidectomy for A Chinese Nationwide large-scale cohort study. J Natl Compr Canc Netw, 2025; 23(3):105–112; doi: 10.6004/jnccn.2024.7088
35.
DuYX, ShenCK, SongKH, et al.Updated thresholds of basal calcitonin level and extent of lymph node metastasis in initially treated medullary thyroid cancer. JAMA Otolaryngol Head Neck Surg, 2025; 151(8):761–767; doi: 10.1001/jamaoto.2025.0542
36.
WellsSAAS, DralleH, EliseiR, et al.; The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015; 25(6):567–610; doi: 10.1089/thy.2014.0335
37.
YadavSK, AgarwalP, SharmaD. Critical view of safety: Anatomical key to avoid injury to recurrent laryngeal nerve in transoral endoscopic thyroidectomy. Laryngoscope, 2025; 135(3):1227–1228; doi: 10.1002/lary.32001
38.
NgoDQ, TruongD, LeDT, et al.Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes. Oral Oncol, 2025; 167(5):107406; doi: 10.1016/j.oraloncology.2025.107406
39.
ChandG, GodiP, KumariM, et al.Trans-oral endoscopic thyroidectomy via vestibular approach (TOETVA): Single-surgeon experience of more than 100 cases. Indian J Surg, 2025; 6; doi: 10.1007/s12262-025-04302-2
40.
AnnebäckM, WachtmeisterS, HedbergJ, et al.Quality of life in patients with permanent hypoparathyroidism after thyroidectomy for benign thyroid disease: Population-based study with long-term follow-up. BJS Open, 2025; 9(3):zraf032; doi: 10.1093/bjsopen/zraf032
41.
ten HoorMBC, LinJF, MetmanMJH, et al.Does a restrictive diagnostic work-up for thyroid nodules lead to a different papillary thyroid cancer patient population? A comparison between Dutch and US T1-T3 patient population. World J Surg, 2025; 49(4):985–996; doi: 10.1002/wjs.12457
